Inventiva S.A.

Inventiva did not disclose revenue, EPS, or gross margin on this call. As of June 30, 2026, cash equivalents and short-term deposits were EUR 233.9 million. In the June capital optimization, the company bought back approximately 60% of the EIB warrants with anti-dilution protection for EUR 50 million, repaid EIB loans for EUR 63 million, and issued new EIB warrants in exchange. It also completed new debt financing of up to EUR 130 million in three committed tranches, with an initial drawdown of EUR 75 million gross plus an additional uncommitted tranche of up to EUR 20 million, and an underwritten ADS offering that generated gross proceeds of EUR 103 million. First-half 2026 expenses included R&D of EUR 46.2 million, marketing and business development of EUR 2.6 million, and G&A of EUR 22.2 million. Management said current resources and completed financings provide runway until the end of Q2 2027, or to the start of Q1 2028 if Tranche 3 warrants are fully exercised and Tranche C is completed. No formal full-year financial guidance was given beyond that runway commentary.

Andrew Obenshain framed the quarter as a defining period, emphasizing that Inventiva is focused on near-term execution rather than broadening the story. He repeatedly highlighted lanifibranor’s potential differentiation in MASH because it targets both metabolic and hepatic drivers, and pointed to the phase IIb NATIVE results as the basis for NATiV3. His tone was upbeat but disciplined, stressing that the company is preparing for regulatory and commercial readiness while waiting for the Q4 readout.

Axel-Sven Malkomes said the June financing and capital structure actions materially strengthened the balance sheet, extended debt maturity, and simplified the structure. He cited EUR 233.9 million of cash equivalents and short-term deposits at June 30, 2026, and said the company has runway to the end of Q2 2027, with potential extension to the start of Q1 2028 if additional financing-linked conditions are met. On the P&L side, he said R&D was EUR 46.2 million in 1H 2026, marketing and business development was EUR 2.6 million, and G&A was EUR 22.2 million.

Analysts focused heavily on NATiV3 readouts, especially the two-dose strategy, the effect of higher F3 enrollment, GLP-1/SGLT2 drop-ins, weight gain, and edema. Management said if both doses are statistically positive, it could make sense to bring both forward depending on efficacy and tolerability, but stressed that final decisions depend on the data. On safety, they said weight gain tended to plateau in prior studies and was not a major discontinuation driver in NATIVE, while edema was generally mild to moderate and mechanistically consistent with partial PPAR-gamma activity; they also said investigators can use diuretics or SGLT2s if needed, but no formal management algorithm is built into the protocol. On trial design, management said GLP-1 drop-ins were allowed only at non-MASH doses, that sensitivity analyses are pre-specified, and that the trial is powered on the primary endpoint rather than subgroup analyses.